John B. Buse
Impact in
- Endocrinology, Diabetes and Metabolism top 0.01%
- Diabetes Treatment and Management
- Diabetes Management and Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmaceutical Science top 0.05%
Papers in
-
- Diabetes Treatment and Management 242
- Diabetes Management and Research 160
- Diabetes, Cardiovascular Risks, and Lipoproteins 41
- Hyperglycemia and glycemic control in critically ill and hospitalized patients 32
-
- Metabolism, Diabetes, and Cancer 89
- Co-authors
- Ele Ferrannini (23 shared papers)Απόστολος Τσάπας (16 shared papers)B Zinman (56 shared papers)Michael Albrecht Nauck (43 shared papers)Richard M. Bergenstal (30 shared papers)Anne L. Peters (21 shared papers)Rury R. Holman (46 shared papers)Michaëla Diamant (8 shared papers)
- Journals
- Diabetes Care (122 papers)Diabetes Obesity and Metabolism (43 papers)Diabetes (32 papers)Diabetologia (22 papers)Diabetes Technology & Therapeutics (10 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
John B. Buse
580 papers receiving 72.8k citations
John B. Buse's Hit Papers
Peers
Comparison fields: 5 of 196
- Endocrinology, Diabetes and Metabolism 46.7k
- Pharmaceutical Science 2.3k
- Surgery 14.7k
- Pharmacology 5.7k
- Physiology 6.8k
Countries citing papers authored by John B. Buse
This map shows the geographic impact of John B. Buse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John B. Buse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John B. Buse more than expected).
Fields of papers citing papers by John B. Buse
This network shows the impact of papers produced by John B. Buse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John B. Buse. The network helps show where John B. Buse may publish in the future.
Co-authors
The 25 scholars most cited alongside John B. Buse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 605 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes Hit paper breakdown → | 2016 | 5559 |
| 2 | Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Hit paper breakdown → | 2012 | 3353 |
| 3 | Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy Hit paper breakdown → | 2008 | 3137 |
| 4 | Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Hit paper breakdown → | 2018 | 2841 |
| 5 | Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Hit paper breakdown → | 2012 | 2737 |
| 6 | Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes Hit paper breakdown → | 2014 | 2505 |
| 7 | Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes Hit paper breakdown → | 2015 | 1994 |
| 8 | The Metabolic Syndrome: Time for a Critical Appraisal Hit paper breakdown → | 2005 | 1929 |
| 9 | Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes Hit paper breakdown → | 2017 | 1637 |
| 10 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Hit paper breakdown → | 2009 | 1278 |
| 11 | Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Hit paper breakdown → | 2018 | 1169 |
| 12 | Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Hit paper breakdown → | 2022 | 1161 |
| 13 | Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes Hit paper breakdown → | 2004 | 1156 |
| 14 | Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy Hit paper breakdown → | 2006 | 979 |
| 15 | Liraglutide and Renal Outcomes in Type 2 Diabetes Hit paper breakdown → | 2017 | 953 |
| 16 | Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Hit paper breakdown → | 2008 | 918 |
| 17 | 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Hit paper breakdown → | 2019 | 893 |
| 18 | Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus Hit paper breakdown → | 2006 | 837 |
| 19 | How Do We Define Cure of Diabetes? Hit paper breakdown → | 2009 | 798 |
| 20 | The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study Hit paper breakdown → | 2010 | 764 |
About John B. Buse
John B. Buse is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery, Genetics and Physiology, having authored 605 papers that have together received 76.3k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (242 papers), Diabetes Management and Research (160 papers), Metabolism, Diabetes, and Cancer (89 papers), Pancreatic function and diabetes (64 papers), Diabetes and associated disorders (43 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (41 papers), Hyperglycemia and glycemic control in critically ill and hospitalized patients (32 papers) and Pharmacology and Obesity Treatment (27 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (46.7k citations), Pharmaceutical Science (2.3k citations), Surgery (14.7k citations), Pharmacology (5.7k citations) and Physiology (6.8k citations). John B. Buse has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Ele Ferrannini, Απόστολος Τσάπας, B Zinman, Michael Albrecht Nauck, Richard M. Bergenstal, Anne L. Peters, Rury R. Holman, Michaëla Diamant, David Richard Matthews and Mayer B. Davidson. Their work appears in journals such as Diabetes Care, Diabetes Obesity and Metabolism, Diabetes, Diabetologia and Diabetes Technology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.